Effects of royal jelly on inflammation in chronic kidney disease patients
Effects of Royal Jelly Supplementation on Inflammation and Cellular Senescence in Chronic Kidney Disease Patients Under Hemodialysis
NA · Universidade Federal Fluminense · NCT06438445
This study is testing if taking royal jelly can help reduce inflammation in people with chronic kidney disease who are on hemodialysis.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Universidade Federal Fluminense (other) |
| Locations | 1 site (Rio de Janeiro, Rio de Janeiro) |
| Trial ID | NCT06438445 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of royal jelly supplementation on inflammation and cellular senescence in patients with chronic kidney disease (CKD) undergoing hemodialysis. Participants will receive either royal jelly or a placebo for 8 weeks, followed by a washout period and crossover to the alternate treatment. The study aims to assess changes in mRNA expression of key transcription factors and inflammatory markers through biological sample collection. This approach seeks to explore the potential benefits of royal jelly's bioactive compounds in mitigating complications associated with CKD.
Who should consider this trial
Good fit: Ideal candidates are patients with chronic kidney disease on hemodialysis for more than six months who have an arteriovenous fistula for vascular access.
Not a fit: Patients who are pregnant, lactating, smokers, or have certain autoimmune diseases, cancers, liver disease, or AIDS may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a novel dietary intervention to reduce inflammation and improve health outcomes for patients with chronic kidney disease.
How similar studies have performed: While there is limited research specifically on royal jelly in this context, the study's approach is novel and has not been extensively tested in chronic kidney disease patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * patients with CKD undergoing hemodialysis for more than 6 months * patients with arteriovenous fistula (AVF) as vascular access. Exclusion Criteria: * pregnant, * lactating, * smoker * patients using antibiotics and antioxidant supplements in the last three months * patients with autoimmune and infectious diseases, * patients with cancer, liver disease, and AIDS
Where this trial is running
Rio de Janeiro, Rio de Janeiro
- Denise Mafra — Rio de Janeiro, Rio de Janeiro, Brazil (RECRUITING)
Study contacts
- Study coordinator: Denise Mafra
- Email: dmafra30@gmail.com
- Phone: 21985683003
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Kidney Failure, Chronic, Oxidative Stress, Hemodialysis, Cellular Senescence, Renal Dialysis, Renal Insufficiency, Chronic